LB Pharmaceuticals
LBRX39.3750.96% ( +0.375 )
LB Pharmaceuticals (LBRX)
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neurops...
- Open
- 39.270
- High
- 39.860
- Low
- 36.720
- Prev. Close
- 39.000
- Volume
- 9.62K
- Turnover
- 374.46K
- Avg Price
- 38.938
- Bid/Ask Ratio
- --
- Amplitude
- 8.05%
- 52wk High
- 39.860
- Volume Ratio
- 0.55
- Turnover Ratio
- 0.06%
LB Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Jul 29, 2026Price forecast
$45.8816.51%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy12.50%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 07:20 AM
LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per share
- rttnews · 1 day ago, 03:23 AM
Biotech Stocks At 52-Week Highs - INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX
- Tip Ranks · Jul 23 at 10:25 AM
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained
- rttnews · Jul 23 at 03:38 AM
Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRX
- benzinga_article · Jul 22 at 12:55 PM
LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.
- PUBT · Jul 22 at 07:04 AM
LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline
